Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH2: ruxolitinib versus best available therapy for steroid-refractory acute graft-versus-host disease
NL-OMON48922Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Novartis. Primary endpoint: Overall response rate at Day 28. Started May 2018; status: active, not recruiting.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NL-OMON48922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48922.